Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05930561 · ClinicalTrials.gov registry record · Phase 2
4D-150 in Patients With Diabetic Macular Edema
A Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by 4D Molecular Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 6
- Study locations
NCT05930561: Active Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by 4D Molecular Therapeutics.
NCT05930561 is a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy that is active but no longer recruiting, run by 4D Molecular Therapeutics. The registered enrollment target is 72 participants, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05930561, a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, is active but no longer recruiting, sponsored by 4D Molecular Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Conditions Studied
Interventions
- BIOLOGICAL 4D-150 IVT
- BIOLOGICAL Aflibercept IVT
Study Locations (6)
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Oregon
- Verum Research, LLC - Eugene
Pennsylvania
- Erie Retina Research - Erie
Texas
- Austin Clinical Research - Austin
Virginia
- Piedmont Eye Center - Lynchburg
Other
- Emanuelli Research and Development Center - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-08-09 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
What the registry record for NCT05930561 still lists
NCT05930561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT is the first listed.
NCT05930561 lists 6 locations in 6 states (Maryland, Oregon, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05930561 about?
NCT05930561 is a clinical study titled "4D-150 in Patients With Diabetic Macular Edema". Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
What is the current status of trial NCT05930561?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2023-08-09. Estimated completion is 2029-02-28.
What conditions does trial NCT05930561 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy.
What interventions are being tested in trial NCT05930561?
The interventions under investigation include: 4D-150 IVT (BIOLOGICAL), Aflibercept IVT (BIOLOGICAL).
Who is sponsoring clinical trial NCT05930561?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05930561 being conducted?
This trial has 6 study locations across Maryland, Oregon, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05930561's enrollment target sits among peer trials
72 35th of 63 higher than 29 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
-
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI